Has Jason Efstathiou, MD received payments from drug or device companies?

Yes. Drug and device makers reported $156,003 in general payments to Jason Efstathiou, MD across 112 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jason Efstathiou, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jason Efstathiou, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jason Efstathiou, MD

Radiation Oncology · Boston, MANPI 1598967523

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $107,250 of the $156,003 with a category attached, or 68.7%. 20 manufacturers reported payments, led by Blue Earth Diagnostics at 31.4% of the total. Among radiation oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$156,003in general payments, 2019–2025

Across 112 payments — averaging $1392.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Blue Earth Diagnostics$49K
Boston Scientific$30K
Bioprotect Medical, Inc.$14K
Progenics Pharmaceuticals, Inc.$9K
Pfizer$8K
Astellas Pharma US Inc$6K
plus $39K from 14 others

$45,875in research payments, 2019–2025

Across 2 payments — averaging $22,938 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Blue Earth Diagnostics$46K

What the payments were for

Consulting fees$107,25069%
Speaking & faculty fees$37,97824%
Travel & lodging$6,9614%
Food & beverage$3,8132%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Blue Earth Diagnostics	23	$49,003
Boston Scientific	31	$30,037
Bioprotect Medical, Inc.	9	$13,897
Progenics Pharmaceuticals, Inc.	6	$9,357
Pfizer	5	$8,342
Astellas Pharma US Inc	3	$6,442
Myovant Sciences Inc.	1	$6,305
Genentech, Inc.	2	$5,997
Angiodynamics, Inc.	15	$5,610
IBA Proton Therapy, Inc.	1	$3,886
Janssen Scientific Affairs, LLC	2	$3,200
Astrazeneca UK Limited	2	$3,000
Merck	1	$2,500
Bayer	1	$2,160
Johnson & Johnson	1	$2,115
Gilead	2	$1,935
Elekta, Inc.	2	$1,575
Genentech USA, Inc.	3	$535
Janssen Global Services, LLC	1	$73
Varian Medical Systems, Inc.	1	$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Axumin$28,503
XTANDI$14,572
GENERAL BPH$14,117
BIOPROTECT BALLOON IMPLANT SYSTEM$13,878
SpaceOAR System$11,007
PYLARIFY$8,802
POSLUMA$6,589
ORGOVYX$6,547
Nanoknife$5,308
Erleada$3,200
Xofigo$2,160
SpaceIT Hydrogel System$1,950
Mosaiq$1,575
GENERAL - THERAPIES$1,500
LOTUS EDGE$647
SPACEOAR$243
SpaceOAR VUE System - 10mL$124
TALZENNA$113

How this compares

$156,003 in reported general payments places this provider in the 95th percentile of 200 radiation oncology providers in Massachusetts.

See all radiation oncology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$283,473

Medicare patients

440

Services billed

2,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	27	$480

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Boston

Peter OrioBoston$1.8M
Paul NguyenBoston$721K
Jonathan SchoenfeldBoston$53K
Martin KingBoston$37K
Raymond MakBoston$36K
Shannon MacdonaldBoston$33K
Nima AghdamBoston$29K
Rachel JimenezBoston$28K
Theodore HongBoston$24K
Alice HoBoston$22K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →